Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06289751
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06289062
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06288360
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳Beiing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital (Southwest Hospital), Army Medical University (Third Military Medical University), Chongqing, Chongqing, China
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 440
- Registration Number
- NCT06288373
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳Beiing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital (Southwest Hospital), Army Medical University (Third Military Medical University), Chongqing, Chongqing, China
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 286
- Registration Number
- NCT06282575
- Locations
- 🇺🇸
The University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States
🇺🇸Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, United States
🇺🇸Laura and Isaac Perlmutter Cancer Center at NYU Langone - Ambulatory Care Center, New York, New York, United States
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial
- Conditions
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Yung NA
- Target Recruit Count
- 20
- Registration Number
- NCT06257017
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT06241235
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Zhejiang, Hangzhou, China
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 351
- Registration Number
- NCT06241456
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Ohio State University - Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Yale New Haven Hospital - Yale Cancer Center, New Haven, Connecticut, United States
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 840
- Registration Number
- NCT06236438
- Locations
- 🇺🇸
University of Kansas Medical Center /ID# 263196, Westwood, Kansas, United States
🇺🇸Memorial Hospital West /ID# 262221, Pembroke Pines, Florida, United States
🇺🇸Bond Clinic /ID# 262611, Winter Haven, Florida, United States
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 216
- Registration Number
- NCT06230224
- Locations
- 🇨🇳
Chang Gung Memorial Hospital Kaohsiung, Kaohsiung City, Taiwan
🇹🇷VM Medical Park Mersin Hospital, Mezitli, Mersin, Turkey
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.